After transplantation of Takeda Pharmaceutical Korea, Cytomegalovirus infection treatment Livtencity obtained domestic item permission and passed the first gateway to supply.

The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) announced on the 27th that it has approved Livtencity of Takeda, a rare drug. Cytomegalovirus (CMV) is asymptomatic and is reactivated, causing serious diseases.

Livticity is an oral antiviral drug that inhibits the growth of the virus by lowering the activity of the "UL97 protein phosphorylation enzyme" involved in cloning and proliferation in CMV.

The drug is expected to provide new treatment opportunities for adult patients with macrophage